Abstract: The invention provides isolated nucleic acids molecules and proteins, designated NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, and NARC 25, nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: The present invention relates to a newly identified human and mouse programmed cell death (PCD) protein having homology to mammalian subtilases. The invention also relates to polynucleotides encoding the protein. The invention further relates to methods using the polypeptides and polynucleotides as a target for diagnosis and treatment in disorders mediated by or related to the protein. The invention further relates to drug-screening methods using the polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the polypeptides and polynucleotides. The invention further relates to procedures for producing the polypeptides and polynucleotides.

Abstract: The invention provides isolated nucleic acids molecules, designated CDAP nucleic acid molecules, which are differentially expressed in cells undergoing programmed cell death. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing CDAP nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a CDAP gene has been introduced or disrupted. The invention still further provides isolated CDAP proteins, fusion proteins, antigenic peptides and anti-CDAP antibodies. Diagnostic methods utilizing compositions of the invention are also provided.